Guaifenesin Taken by Mouth for Excess Mucus in Bronchitis
Tests guaifenesin against usual care for mucus thickness in people with bronchitis.
Plain-language title generated from the registry record
Registry title: Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion
Key facts
- Where
- Chapel Hill, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07873632, who can take part
Where in United States
- Marsico Lung InstituteChapel Hill, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of North Carolina, Chapel Hill
- Trial code
- NCT07873632
- Record updated
- 14 October 2026
- Original description
A Randomized, Dosing vs Standard of Care, Single-Center, Multiple Dose Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus HypersecretionRead full original descriptionShow less
A Randomized, Dosing vs Standard of Care, Single-Center, Multiple Dose Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion
A Randomized, Dosing vs Standard of Care, Single-Center, Multiple Dose Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion
Inclusion: • Confirmed diagnosis of stable chronic bronchitis (defined as subjects with chronic productive cough that occurs daily for at least 3 months in 2 consecutive years, in a patient who has not had an acute exacerbation within the previous 4 weeks; where an acute exacerbation of chronic bronchitis is defined as an acute worsening of a patient's symptoms, beyond normal day-to-day variations, necessitating a change in treatment with antibiotics and/or corticosteroids); Ability to produce spontaneous sputum and non-reactive to hypertonic saline for induced sputum collection; Stable disease (no exacerbations requiring hospitalization in the past 28 days); A Pulmonary Function Test with Forced Expiratory Volume in 1st second (FEV1) FEV1/Forced Vital Capacity (FVC) less than 0.7 (70%) but greater than 0.4 (40%) at the time of enrollment and at least a 10-year history of cigarette use; Participants who have not used guaifenesin-containing products within one month of the time of study enrollment; Adults age 40-75 with stable chronic bronchitis with persistent cough.
Exclusion: • Current use of mucolytics (e.g., N-acetylcysteine), corticosteroids, or other GGEs known to alter mucus properties; Severe comorbidities (e.g., Gastroesophageal Reflux Disease (GERD), heart failure, advanced Chronic Obstructive Pulmonary Disease (COPD,) or cystic fibrosis); Smokers (within the past year). Note: Participants with a positive cotinine test at the baseline visit will be dropped from the study; Recent viral infection or other pulmonary exacerbation (< 1 month); Participants who are pregnant or breastfeeding; Pulmonary diagnosis other than Chronic Bronchitis (CB) (such as cystic fibrosis, alpha-1 antitrypsin deficiency, bronchiectasis, or pulmonary fibrosis) or active lung cancer; Participation in another study involving an investigational product within 30 days of the baseline visit; Known allergy to the study GGE or its components; History of alcohol and/or drug abuse within one year of study start; Participants taking intermittent antibiotics and participants taking oral and systemic corticosteroids (e.g., prednisone at a dose of > 10 mg/day). (Note: Participants on a chronic stable dose of macrolide antibiotics at the start of the study may be included at the discretion of the Principal Investigator.); Participants who had an acute exacerbation of chronic bronchitis within one month of starting the study that required systemic steroids or antibiotics; Hypersensitivity to hypertonic saline, guaifenesin, or any other excipient listed in the product; Inability to provide informed consent.